Phenotypes associated with this allele

• Allele Symbol: Rbl2^tm2Tyj
• Allele Name: targeted mutation 2, Tyler Jacks
• Allele ID: MGI:3706581
• Summary: 3 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Rb1^tm2Brn/Rb1^tm2Brn Rbl1^tm1Tyj/Rbl1^tm1Tyj Rbl2^tm2Tyj/Rbl2^tm2Tyj	involves: 129 * 129S2/SvPas * 129S4/SvJae	MGI:5789748
cn2	Rb1^tm3Tyj/Rb1^tm3Tyj Rbl2^tm2Tyj/Rbl2^tm2Tyj Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S4/SvJae	MGI:4459447
cn3	Kras^tm4Tyj/Kras^+ Rbl2^tm2Tyj/Rbl2^tm2Tyj	involves: 129S4/SvJae	MGI:3842378

Genotype
MGI:5789748

cn1

• Allelic Composition: Rb1^tm2Brn/Rb1^tm2Brn; Rbl1^tm1Tyj/Rbl1^tm1Tyj; Rbl2^tm2Tyj/Rbl2^tm2Tyj
• Genetic Background: involves: 129 * 129S2/SvPas * 129S4/SvJae

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased urinary bladder carcinoma incidence ( J:217195 )

• mice injected with an adenovirus expressing cre-recombinase (AdCre) into the bladder lumen all develop bladder lesions that resemble high-grade non-muscle-invasive carcinoma

• bladder tumors display high proliferation and invade the basal lamina

• metastases are not seen for up to 1 year after AdCre infection

renal/urinary system

hematuria ( J:217195 )

• hematuria is sometimes seen in mice injected with AdCre into the bladder lumen with bladder lesions

increased urinary bladder carcinoma incidence ( J:217195 )

• mice injected with an adenovirus expressing cre-recombinase (AdCre) into the bladder lumen all develop bladder lesions that resemble high-grade non-muscle-invasive carcinoma

• bladder tumors display high proliferation and invade the basal lamina

• metastases are not seen for up to 1 year after AdCre infection

homeostasis/metabolism

hematuria ( J:217195 )

• hematuria is sometimes seen in mice injected with AdCre into the bladder lumen with bladder lesions

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
urinary bladder cancer		DOID:11054	OMIM:109800	J:217195

Genotype
MGI:4459447

cn2

• Allelic Composition: Rb1^tm3Tyj/Rb1^tm3Tyj; Rbl2^tm2Tyj/Rbl2^tm2Tyj; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJae

mortality/aging

premature death ( J:160148 )

• adeno-cre-treated mice begin to die at 17 weeks and by 6 months all mice are moribund

neoplasm

increased lung tumor incidence ( J:160148 )

• 3 and 6 months, adeno-cre-treated mice exhibit primary lung tumors with metastasis to the liver unlike wild-type mice

• at 3 and 6 month, adeno-cre-treated mice exhibit more tumors than in similarly treated Rb1^tm3Tyj Trp53^tm1Brn homozygotes

• adeno-cre-treated mice exhibit few lung adenocarcinomas, adenocarcinomas with neuroendocrine features, large-cell neuroendocrine carcinoma, and large-cell carcinomas while most tumors resemble neuroendocrine small-cell lung tumors

increased lung small cell carcinoma incidence ( J:160148 )

• most tumors in adeno-cre-treated mice resemble those found in human neuroendocrine small cell lung cancer patients

respiratory system

increased lung tumor incidence ( J:160148 )

• 3 and 6 months, adeno-cre-treated mice exhibit primary lung tumors with metastasis to the liver unlike wild-type mice

• at 3 and 6 month, adeno-cre-treated mice exhibit more tumors than in similarly treated Rb1^tm3Tyj Trp53^tm1Brn homozygotes

• adeno-cre-treated mice exhibit few lung adenocarcinomas, adenocarcinomas with neuroendocrine features, large-cell neuroendocrine carcinoma, and large-cell carcinomas while most tumors resemble neuroendocrine small-cell lung tumors

increased lung small cell carcinoma incidence ( J:160148 )

• most tumors in adeno-cre-treated mice resemble those found in human neuroendocrine small cell lung cancer patients

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
lung small cell carcinoma		DOID:5409	OMIM:182280	J:160148

Genotype
MGI:3842378

cn3

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Rbl2^tm2Tyj/Rbl2^tm2Tyj
• Genetic Background: involves: 129S4/SvJae

mortality/aging

premature death ( J:147590 )

• median life span of cre adenovirus-treated mice is 25 weeks

neoplasm

abnormal tumor morphology ( J:147590 )

• tumors from cre adenovirus-treated mice exhibit lower cell proliferation rates compared to in tumors from Kras^tm4Tyj heterozygotes and Kras^tm4Tyj/Kras⁺ Rb1^tm3Tyj/Rb1^tm3Tyj mice

increased tumor growth/size ( J:147590 )

• cre adenovirus-treated mice develop larger tumors than in cre adenovirus-treated Kras^tm4Tyj heterozygotes and Kras^tm4Tyj/Kras⁺ Rb1^tm3Tyj/Rb1^tm3Tyj mice

increased lung tumor incidence ( J:147590 )

• mice treated with adenovirus cre develop lung lesions in 4 to 6 months

• cre adenovirus-treated mice develop lung adenocarcinomas, papillary adenomas and bronchiolar hyperplasia and dysplasia

increased lung adenocarcinoma incidence ( J:147590 )

• in cre adenovirus-treated mice

respiratory system

increased lung tumor incidence ( J:147590 )

• mice treated with adenovirus cre develop lung lesions in 4 to 6 months

• cre adenovirus-treated mice develop lung adenocarcinomas, papillary adenomas and bronchiolar hyperplasia and dysplasia

increased lung adenocarcinoma incidence ( J:147590 )

• in cre adenovirus-treated mice

thick pulmonary interalveolar septum ( J:147590 )

• in cre-adenovirus-treated mice

abnormal bronchiole morphology ( J:147590 )

• cre adenovirus-treated mice develop bronchiolar hyperplasia and dysplasia unlike wild-type mice